These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25581761)

  • 41. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine.
    Ferro M; Lucarelli G; Bruzzese D; Perdonà S; Mazzarella C; Perruolo G; Marino A; Cosimato V; Giorgio E; Tagliamonte V; Bottero D; De Cobelli O; Terracciano D
    Anticancer Res; 2015 Feb; 35(2):1017-23. PubMed ID: 25667489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
    Song J; Ma S; Sokoll LJ; Eguez RV; Höti N; Zhang H; Mohr P; Dua R; Patil D; May KD; Williams S; Arnold R; Sanda MG; Chan DW; Zhang Z
    Theranostics; 2021; 11(13):6214-6224. PubMed ID: 33995654
    [No Abstract]   [Full Text] [Related]  

  • 43. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
    Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
    Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p.
    Tölle A; Jung K; Friedersdorff F; Maxeiner A; Lein M; Fendler A; Stephan C
    Cancer Biomark; 2021; 30(4):381-393. PubMed ID: 33361585
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New biomarkers for diagnosis and prognosis of localized prostate cancer.
    Chistiakov DA; Myasoedova VA; Grechko AV; Melnichenko AA; Orekhov AN
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):9-16. PubMed ID: 29360504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [New biomarkers in prostate cancer].
    Provenzano M
    Praxis (Bern 1994); 2012 Jan; 101(2):115-21. PubMed ID: 22252593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
    Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
    BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Taneja SS
    J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
    [No Abstract]   [Full Text] [Related]  

  • 50. Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis.
    Neves AF; Dias-Oliveira JD; Araújo TG; Marangoni K; Goulart LR
    Clin Chem Lab Med; 2013 Apr; 51(4):881-7. PubMed ID: 23241599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
    Neves AF; Araújo TG; Biase WK; Meola J; Alcântara TM; Freitas DG; Goulart LR
    Clin Biochem; 2008 Oct; 41(14-15):1191-8. PubMed ID: 18640109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals.
    Capoluongo E; Zambon CF; Basso D; Boccia S; Rocchetti S; Leoncini E; Palumbo S; Padoan A; Albino G; Todaro A; Prayer-Galetti T; Zattoni F; Zuppi C; Plebani M
    Clin Chim Acta; 2014 Feb; 429():46-50. PubMed ID: 24269853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).
    Stephan C; Rittenhouse H; Hu X; Cammann H; Jung K
    EJIFCC; 2014 Apr; 25(1):55-78. PubMed ID: 27683457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy.
    Seisen T; Rouprêt M; Brault D; Léon P; Cancel-Tassin G; Compérat E; Renard-Penna R; Mozer P; Guechot J; Cussenot O
    Prostate; 2015 Jan; 75(1):103-11. PubMed ID: 25327361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Urinary Biomarkers for Prostate Cancer.
    Tosoian JJ; Ross AE; Sokoll LJ; Partin AW; Pavlovich CP
    Urol Clin North Am; 2016 Feb; 43(1):17-38. PubMed ID: 26614026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent progress and perspectives on prostate cancer biomarkers.
    Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
    Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PSA and beyond: alternative prostate cancer biomarkers.
    Saini S
    Cell Oncol (Dordr); 2016 Apr; 39(2):97-106. PubMed ID: 26790878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients].
    Houlgatte A; Vincendeau S; Desfemmes F; Ramirez J; Benoist N; Bensalah K; Durand X
    Prog Urol; 2012 May; 22(5):279-83. PubMed ID: 22515924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.